Application of isolindelactone as endoplasmic reticulum stress agent in preparation of pancreatic cancer inhibitor
By using the lipid of Isomalgia as an endoplasmic reticulum stress agent, it activates the P38 MAPK signaling pathway, increases DDIT3 expression, and inhibits the proliferation and migration of pancreatic cancer cells, it solves the problem of pancreatic cancer treatment in the prior art and provides a new Effective treatment plan.
Patent Information
- Application Number
- CN202410988309.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-23
- Publication Date
- 2024-11-12
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The prior art is difficult to effectively treat pancreatic cancer, especially after the emergence of gemcitabine resistance, there is a lack of new and good tolerant treatment options, and there is no research result in pancreatic cancer treatment in the treatment of IVF.
Using lipids of IVF as an endoplasmic reticulum stress agent, increases DDIT3 expression by activating the P38 MAPK signaling pathway, induces apoptosis and cell cycle arrest, inhibits the proliferation, migration and invasion of pancreatic cancer cells, and is applied to pancreatic cancer inhibition. in the agent.
The lipids of IVF significantly inhibited the proliferation, migration and invasion of pancreatic cancer cells in both in vivo and in vitro experiments, providing a new natural compound candidate for the treatment of pancreatic cancer, with high anti-tumor activity.
Smart Images

Figure CN118924736A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of pharmaceutical chemistry, and in particular to an application of isocarpin as an endoplasmic reticulum stress agent in the preparation of a pancreatic cancer inhibitor. Background Art
[0002] Pancreatic cancer is a rapidly progressing malignant tumor. More than 80% of patients have lost the opportunity for surgery when diagnosed. Even for patients who can undergo surgery, the recurrence rate after surgery is very high. Therefore, chemotherapy is one of the important ways to treat pancreatic cancer for most patients. However, the drug resistance of pancreatic tumors is another huge challenge that patients need to face. Currently, the gemcitabine-paclitaxel combination regimen is widely used to treat pancreatic cancer. Although many patients initially respond well to gemcitabine, they gradually develop drug resistance after a short period of time and eventually lose the effect of suppressing tumors, and a new treatment regimen is needed. Although more and more drugs have been developed for the clinical treatment of pancreatic cancer in the past 20-30 years, most patients still lack suitable therapeutic drugs in the later stages of treatment. Therefore, new, effective and well-tolerated pancreatic cancer treatment compounds are urgently needed. Isolinol (ILL) is a major extract of Linderae serrata and a sesquiterpenoid compound. Previously, a small number of studies have reported the anti-tumor effects of Isolinol, which can induce apoptosis of ovarian cancer by inhibiting the STAT3 signaling pathway. In addition, isocarpin can inhibit the proliferation and migration of lung cancer by inhibiting the cell cycle.
[0003] The endoplasmic reticulum is one of the main sites for cell protein processing. When unfolded and misfolded proteins accumulate in the endoplasmic reticulum lumen, leading to endoplasmic reticulum dysfunction, endoplasmic reticulum stress is triggered. The vast majority of endoplasmic reticulum stress is involved in three pathways, namely IRE1, PERK and ATF6. These pathways can trigger the unfolded protein response, such as the activation of the PERK / ATF4 pathway caused by endoplasmic reticulum stress, restore the redox level and promote the biosynthesis and transport of amino acids, and promote cell survival. However, when cells face long-term ERS conditions, cells will initiate endogenous apoptosis programs. When the time and intensity of stress increase, ATF4 and ATF6 can induce the expression of DDIT3, and IRE1 can activate c-Jun N-terminal kinase, triggering the expression of apoptosis-related proteins in cells. Therefore, for the treatment of tumors, some anti-tumor drugs targeting endoplasmic reticulum stress have been developed, such as Edelfosine for the treatment of leukemia and BiP inhibitor HA15 for the treatment of melanoma.
[0004] There have been no previous research results on the inhibition of pancreatic cancer by isothiocyanate, nor have there been any studies on the treatment of tumors by promoting endoplasmic reticulum stress by isothiocyanate.
[0005] In view of the above-mentioned defects, the inventors of the present invention finally obtained the present invention after a long period of research and practice. Summary of the invention
[0006] The purpose of the present invention is to solve the problem of how to use isocladium lactone in the preparation of a medicament for treating tumors by promoting endoplasmic reticulum stress, and provides an application of isocladium lactone as an endoplasmic reticulum stress agent in the preparation of a pancreatic cancer inhibitor.
[0007] In order to achieve the above object, the present invention discloses an application of isocladium lactone as an endoplasmic reticulum stress agent in the preparation of a pancreatic cancer inhibitor. The structure of the isocladium lactone is as follows:
[0008]
[0009] The pancreatic cancer cells are four pancreatic cancer cell lines, namely, ASPC-1, BXPC-3, CFPAC-1 and SW 1990.
[0010] The effective concentration of the isocarpin is 5 mg / kg to 10 mg / kg.
[0011] In the in vitro test, the effective concentration of the isocarpin was ≥20 μM.
[0012] The invention also discloses an application of isocladium lactone in preparing CFPAC-1 and SW 1990 cell invasion and migration inhibitors. In an in vitro test, the action concentration of the isocladium lactone is 20 μM to 40 μM, and the action time is 24 hours.
[0013] The invention also discloses an application of isocladium lactone in preparing CFPAC-1 and SW 1990 cell cycle arrest and apoptosis promoter. In an in vitro test, the action concentration of the isocladium lactone is 20 μM to 40 μM, and the action time is 24 hours.
[0014] The invention also discloses an application of isoclofolate in preparing a p38MAPK signaling pathway promoter in CFPAC-1 and SW 1990 cells. In an in vitro test, the action time of the isoclofolate is 24 hours.
[0015] The invention also discloses an application of isolindrospermum officinale in preparing an endoplasmic reticulum stress promoter in CFPAC-1 and SW 1990 cells.
[0016] The invention also discloses an application of isolindrospermuminosae lactone in preparing a high expression promoter of DDIT3 in CFPAC-1 and SW 1990 cells.
[0017] Compared with the prior art, the beneficial effect of the present invention is that: the present invention provides an application of isocladium lactone in the preparation of anti-pancreatic cancer activity, which is specifically reflected in that isocladium lactone has obvious anti-pancreatic cancer effects in both in vivo animal experiments and in vitro cell experiments, and the half-inhibitory concentrations in four pancreatic cancer cells are ASPC-1: 28.85μM, BXPC-3: 29.79μM, CFPAC-1: 33.82μM, SW 1990: 35.24μM. In addition, the present invention reveals the way in which isocladium lactone inhibits pancreatic cancer. First, isocladium lactone stimulates the activation of the P38 MAPK signaling pathway in pancreatic cancer, aggravates the degree of endoplasmic reticulum stress in tumor cells, further stimulates the expression of DDIT3, and induces the inhibition of tumor characteristics such as cell apoptosis, proliferation inhibition, and cycle arrest. The present invention is expected to provide candidate drugs for natural compounds as pancreatic cancer treatment. BRIEF DESCRIPTION OF THE DRAWINGS
[0018] Figure 1 is the structural formula of iso-lindera lactone;
[0019] Figure 2 is the ability of isocladium lactone to inhibit the proliferation of pancreatic cancer, wherein A is the observation of cells under phase contrast microscope, B is the cell activity under different concentrations of isocladium lactone and different treatment time; C is the cell staining after incubation with different concentrations of isocladium lactone, D is the proportion of cells stained with EdU after incubation with different concentrations of isocladium lactone, E is the pancreatic cancer cell clones under microscope observation, and F is the number of pancreatic cancer cell clones;
[0020] Figure 3 The inhibition of pancreatic cancer migration and invasion by isocarpin, where A is the migration of pancreatic cancer cells under microscope, B is the migration distance of pancreatic cancer cells, C is the migration of pancreatic cancer cells under phase contrast microscope, and D is the number of pancreatic cancer cells that migrated; E is the invasion of pancreatic cancer cells under phase contrast microscope, and F is the number of pancreatic cancer cells that invaded;
[0021] Figure 4 Isophyllotoxin blocks pancreatic cancer cell cycle at G2 / M phase and induces cell apoptosis, where A and B are the cell cycle distribution detected by flow cytometry; C and D are the apoptosis of pancreatic cancer cells;
[0022] Figure 5 Isobacterium lactone inhibits pancreatic cancer by activating p38 MAPK signaling, wherein AC is the effect of isobacterium lactone on p38 MAPK signaling pathway, DE is the effect of isobacterium lactone on p38 signaling pathway, and F is the cloning of pancreatic cancer cells after treatment with different concentrations of reagents;
[0023] Figure 6Isobacterium lactone promotes DDIT3 to inhibit pancreatic cancer through p38, where A is the difference in expression of DDIT3 in the p38 MAPK signaling pathway after isobacterium lactone treatment, B is the expression level of DDIT3 mRNA, CD is the effect of isobacterium lactone on the expression of DDIT3 protein level, and E is the effect of isobacterium lactone on pancreatic cancer cells after inhibiting and knocking down DDIT3;
[0024] Figure 7 Isobacterium lactone can induce high endoplasmic reticulum stress, among which AB is the significant enrichment of endoplasmic reticulum stress and the difference in folded protein response after isobacterium lactone treatment, C is the endoplasmic reticulum tracing under a fluorescence microscope, D is the stained cells photographed under a fluorescence microscope, and E is the endoplasmic reticulum stress-related signal after using isobacterium lactone;
[0025] Figure 8 To show that isocladium lactone can inhibit the progression of pancreatic cancer in animal models, A is the injection flow chart of mice, BE is the weight of mice and the length and width of tumors, and F is the weight of mice after using isocladium lactone and the control group. DETAILED DESCRIPTION
[0026] The above and other technical features and advantages of the present invention are described in more detail below in conjunction with the accompanying drawings.
[0027] 1. The ability of isocarpin to inhibit the proliferation of pancreatic cancer
[0028] 1. Cell morphology observation revealed that isocarpin changes the morphology of pancreatic cancer cells
[0029] Four pancreatic cancer cell lines (ASPC-1, BXPC-3, CFPAC-1SW 1990) were plated at 9×10 4 Cells were seeded in 6-well plates and treated with gradient concentrations of isothiocyanate (0 μM, 20 μM, 40 μM). After 72 hours, the changes in cells were observed under a phase contrast microscope ( Figure 2 A) All cell lines behaved similarly under the action of ILL. The number of cells decreased with increasing ILL concentrations, and they lost their original morphology and shrank into a round shape. In addition, the amount of cell debris increased significantly.
[0030] 2. CCK8 detection of cell activity revealed that isocarpin inhibited pancreatic cancer activity in a time-measured manner
[0031] Four pancreatic cancer cell lines (ASPC-1, BXPC-3, CFPAC-1SW 1990) were planted in 96-well plates, with 3000 cells per well. Cell lines were treated with different concentrations of isothiocyanate (0μM, 10μM, 15μM, 20μM, 25μM, 30μM, 35μM, 40μM, 50μM) and different treatment times (24 hours, 48 hours, 72 hours), and CCK8 (10 microliters per well, incubated at 37 degrees for 1 hour) was used to detect cell activity. The activity of all pancreatic cancer cells decreased with increasing concentration and time ( Figure 2 B), 24h IC50 values are ASPC-1: 28.85 μM, BXPC-3: 29.79 μM, CFPAC-1: 33.82 μM, SW 1990: 35.24 μM.
[0032] 3. EdU detection of cell proliferation ability found that isocarpin inhibited the proliferation of pancreatic cancer
[0033] 1.7 × 10 4 The cells were incubated with a medium containing iso-EdU (0 μM, 20 μM, 40 μM), and after 19 hours, the medium was changed to 10 μM EdU for 5 hours, fixed with 4% paraformaldehyde, and treated with TritonX-100 for 10 minutes. Next, the cell nuclei were stained with DAPI for 10 minutes in the absence of light, and observed under a fluorescence microscope. The proportion of cells stained with EdU decreased with the decrease of iso-EdU concentration ( Figure 2 CD), indicating that isocarpin can inhibit the proliferation ability of pancreatic cancer.
[0034] 4. Cell cloning experiments revealed that isothiocyanate inhibited the proliferation and stemness of pancreatic cancer cells
[0035] Pancreatic cancer cells (750 cells per well) were seeded into 6-well plates, and visible clusters were observed after 3 days of culture. After 1 day of treatment with different concentrations of isothiocyanate (0μM, 20μM, 40μM), normal culture medium was replaced and cultured for 1 week. After removing the culture medium and washing twice with PBS, the cells were fixed with 4% paraformaldehyde for half an hour and then stained with 1% crystal violet staining solution. The number of clones was counted. Results ( Figure 2 EF) found that the number of cell clones decreased with the increase of the concentration of isothiocyanate.
[0036] 2. Isophylline inhibits the migration and invasion of pancreatic cancer
[0037] 1. Scratch experiment found that isothiocyanate inhibited the horizontal migration ability of pancreatic cancer cells
[0038] Pancreatic cancer cells were seeded in 6-well plates (1×106 ) overnight and ensure that the cell confluence is greater than 90%. Incubate in serum-free RPMI-1640 medium for 24 hours to eliminate the interference of cell proliferation on the experiment. Use a pipette tip to scrape the cells vertically, and then add serum-free medium with different concentrations of isothiocyanate (0μM, 20μM, 40μM). Observe and take pictures using a phase contrast microscope at 0 hours and 24 hours respectively. Use ImageJ to calculate the distance of cell migration. Results ( Figure 3 AB) found that the cell migration ability decreased with the increase of the concentration of isothiocyanate.
[0039] 2. Transwell assay found that isothiocyanate inhibited the 3D migration ability of pancreatic cancer cells
[0040] Transwell cell culture chambers with 8 μm pore membranes were placed in 24-well plates and pancreatic cancer cells (2×10 5 Each well) serum-free suspension containing different concentrations of isothiocyanate (0μM, 20μM, 40μM) was inoculated in the upper chamber, and 20% FBS culture medium was added to the lower chamber as a chemical inducer. After 16 hours, the cells were fixed with paraformaldehyde, the cells on the upper layer of the membrane were wiped off with a cotton swab, and stained with crystal violet staining solution. Phase contrast microscopy was used to record, and ImageJ was used to count the cells that passed through the membrane. Results ( Figure 3 CD) found that the cell migration ability decreased with the increase of the concentration of isothiocyanate.
[0041] 3. Transwell assay found that isocarpin inhibited the invasion ability of pancreatic cancer cells
[0042] Transwell invasion assay uses a chamber with Matrigel placed in a 24-well plate to inoculate pancreatic cancer cells (2×10 5 Each well) serum-free suspension containing different concentrations of isothiocyanate (0μM, 20μM, 40μM) was inoculated in the upper chamber, and 20% FBS culture medium was added to the lower chamber as a chemical inducer. After 24 hours, the cells were fixed with paraformaldehyde, the cells on the upper layer of the membrane were wiped off with a cotton swab, and stained with crystal violet staining solution. Phase contrast microscopy was used to record, and ImageJ was used to count the cells that passed through the membrane. Results ( Figure 3 EF) found that the cell invasion ability decreased with the increase of the concentration of isothiocyanate.
[0043] 3. Isophylline blocks pancreatic cancer cell cycle at G2 / M phase and induces apoptosis
[0044] 1. Flow cytometry analysis revealed that isothiocyanate inhibited the G2 / M phase of pancreatic cancer cell cycle
[0045] PI staining was used to detect the cell cycle in flow cytometry. Pancreatic cancer cells (9×10 4 Each well) was inoculated overnight in a 6-well plate. Different concentrations of isothiocyanate (0 μM, 20 μM, 40 μM) were used for treatment for 24 hours. After the cells were collected, they were fixed with 70% pre-cooled ethanol for 12 hours. They were mixed with propidium iodide staining solution at 37°C in the dark for 30 minutes. The cell cycle distribution was detected by flow cytometry ( Figure 4 AB), it was found that the proportion of cells in the G2 / M phase increased significantly, indicating that isocarpine blocked the pancreatic cancer cell cycle at the G2 / M phase.
[0046] 2. Flow cytometry apoptosis assay found that isocarpin induced apoptosis of pancreatic cancer cells
[0047] Annexin V / PI staining was used to detect cell apoptosis. Pancreatic cancer cells (9×10 4 Each well) was inoculated overnight in a 6-well plate. Different concentrations of isocladium lactone (0μM, 20μM, 40μM) were used for treatment for 24 hours, and the treated cells were collected. 5μL annexin V and 1μL PI were added to each sample, incubated at room temperature in the dark for 15 minutes, and the excitation light at 530nm was detected by flow cytometry. The results showed that the proportion of apoptotic cells increased with the increase of isocladium lactone concentration ( Figure 4 CD).
[0048] 4. Isophyllotoxin inhibits pancreatic cancer by activating p38 MAPK signaling
[0049] 1. Transcriptome sequencing revealed that isocarpin activates p38 MAPK signaling
[0050] Pancreatic cancer cells (9×10 per well) 4 Each well) was inoculated overnight in a 6-well plate. Different concentrations of iso-lindole lactone (0 μM, 20 μM, 40 μM) were used for 24 hours, and the cellular RNA stored in trizol was extracted using an RNA extraction kit (Qiagen), followed by agarose gel electrophoresis. The sequencing library was obtained by Shanghai Ouyi Company using Stranded TotalRNA Prep was constructed. Differential genes were found and potential signaling pathways were predicted using KEGG enrichment analysis. It was found that isocarpin can activate the p38 MAPK signaling pathway ( Figure 5 AC).
[0051] 2. Western Blot analysis revealed that isocarpin activates p38 MAPK signaling
[0052] Pancreatic cancer cells (9×10 per well) 4Each well) was inoculated overnight in a 6-well plate. Different concentrations of isocladium lactone (0μM, 20μM, 40μM) were used for treatment for 24 hours. The samples were collected and lysed in PIPA lysis buffer with protease and phosphatase inhibitors, added to 5X loading buffer, and boiled at 95°C for 5 minutes. The cell lysate was then electrophoresed with 10% SDS-page gel and transferred to a PVDF membrane. The membrane was incubated in p-P38 antibody overnight, washed three times with TBST the next day, and then secondary antibody was added for 90 minutes. Color was developed in a chemiluminometer. It was found that the phosphorylated p38 signal increased significantly after the use of isocladium lactone, indicating that isocladium lactone can activate the p38 signaling pathway ( Figure 5 DE).
[0053] The clone formation test found that pancreatic cancer cells (750 cells per well) were seeded into 6-well plates, and visible clusters were observed after 3 days of culture. After 1 day of treatment with different concentrations of reagents (basal culture medium, 40μM isophylline, MAPK-IN-1, 40μM isophylline + MAPK-IN-1), normal culture medium was replaced and cultured for 1 week. After removing the culture medium and washing twice with PBS, the cells were fixed with 4% paraformaldehyde for half an hour and then stained with 1% crystal violet stain. The number of clones was counted. Results ( Figure 5 F) It was found that inhibition of p38 inhibitor MAPK-IN-1 could restore the inhibitory effect of isocladium lactone on pancreatic cancer, indicating that isocladium lactone inhibits pancreatic cancer by activating p38 MAPK signaling.
[0054] 5. Isophylline promotes DDIT3 to inhibit pancreatic cancer via p38
[0055] Heat map showing the expression difference of DDIT3 in p38 MAPK signaling pathway after treatment with isocarpin ( Figure 6 A).
[0056] 1. Fluorescence quantitative PCR detection found that DDIT3 mRNA was upregulated after the action of isothiocyanate
[0057] RNA was extracted using an RNA extraction kit (Takara) before and after treatment with iso-Agilent lactone, and reverse transcribed into cDNA using a reverse transcriptase kit (Takara). 1 μl of cDNA was used as a template and CWBIO fluorescent quantitative reagent was used. The reagent was run on a fluorescent quantitative PCR instrument to detect the expression of DDIT3 mRNA. Figure 6B) DDIT3 was upregulated at the mRNA level after treatment with isothiocyanate. The primer sequences were DDIT3 Forward Primer: GGAAACAGAGTGGTCATTCCC. DDIT3 Reverse Primer: CTGCTTGAGCCGTTCATTCTC, ACTB Forward Primer: CATGTACGTTGCTATCCAGGC, ACTB Reverse Primer: CTCCTTAATGTCACGCACGAT.
[0058] 2. Western Blot analysis revealed that p38 inhibitors can inhibit the expression of DDIT3
[0059] Pancreatic cancer cells (9×10 per well) 4 Each well) was inoculated overnight in a 6-well plate. Different concentrations of isocladium lactone (0μM, 20μM, 40μM) were used for treatment for 24 hours. The samples were collected and lysed in PIPA lysis buffer with protease and phosphatase inhibitors, added to 5X loading buffer, and boiled at 95°C for 5 minutes. The cell lysate was then electrophoresed with 10% SDS-page gel and transferred to a PVDF membrane. The membrane was incubated in DDIT3 antibody overnight, washed three times with TBST the next day, and 2 antibodies were added for 90 minutes. Color was developed in a chemiluminometer. It was found that the DDIT3 signal increased significantly after the use of isocladium lactone, and the expression of DDIT3 could be inhibited by the use of p38 inhibitors, indicating that isocladium lactone can promote the expression of DDIT3 protein levels ( Figure 6 CD).
[0060] 3. Cloning assay found that knocking down DDIT3 can restore the inhibitory effect of isothiocyanate on pancreatic cancer
[0061] Pancreatic cancer cells (750 cells per well) were seeded into 6-well plates, and visible clusters were observed after 3 days of culture. After 1 day of treatment with different concentrations of reagents (basal medium, 40 μM isothiocyanate, siDDIT3, 40 μM isothiocyanate + siDDIT3), normal medium was replaced and cultured for 1 week. After removing the medium and washing twice with PBS, the cells were fixed with 4% paraformaldehyde for half an hour and then stained with 1% crystal violet stain. The number of clones was counted. Results ( Figure 6 E) It was found that inhibiting and knocking down DDIT3 could restore the inhibitory effect of isothiocyanate on pancreatic cancer, indicating that isothiocyanate inhibits pancreatic cancer by promoting DDIT3 expression.
[0062] 6. Isophylline can induce high endoplasmic reticulum stress
[0063] KEGG analysis found that the transcriptome data were analyzed using KEGG enrichment analysis, and the results showed that endoplasmic reticulum stress was significantly enriched and the folded protein response was significantly different after treatment with isocarpin ( Figure 7 AB).
[0064] 1. Endoplasmic reticulum tracing shows that isoindigoferol promotes endoplasmic reticulum stress
[0065] ER-Tracker Green was purchased from Bio-Tech. After removing the culture medium, the cells were washed with Hanks' Balanced Salt Solution. The 1:1000 diluted ER-Tracker Green staining solution was incubated with the cells. After 30 minutes, the working solution was washed away and the nuclei were stained with DAPI staining solution for 10 minutes. The cells were observed and photographed under a 40X fluorescence microscope. Results ( Figure 7 C) shows that isocarpin can promote endoplasmic reticulum stress in pancreatic cancer cells.
[0066] Protein aggregation test found that isothiocyanate promotes protein aggregation. The samples treated with different conditions were treated with culture medium, washed twice with PBS, and then treated with 4% paraformaldehyde for 30 minutes. The samples were incubated with permeabilization solution (0.5% Triton X-100, 3mm EDTA, pH 8.0) and shaken on ice for 30 minutes. Incubated with aggregation detection reagent for 30 minutes at 37 degrees Celsius in the dark. The cell nuclei were stained with hoechst 33342 dye. The stained cells were photographed by fluorescence microscopy. Results ( Figure 7 D) shows that isothiocyanate can promote the aggregation of unfolded proteins.
[0067] 2. Western Blot analysis revealed that iso-lindole lactone promoted the expression of endoplasmic reticulum stress-related proteins
[0068] Pancreatic cancer cells (9×10 per well) 4 Each well) was inoculated overnight in a 6-well plate. Different concentrations of isocladium lactone (0μM, 20μM, 40μM) were used for treatment for 24 hours. The samples were collected and lysed in PIPA lysis buffer with protease and phosphatase inhibitors, added to 5X loading buffer, and boiled at 95°C for 5 minutes. The cell lysate was then electrophoresed with 10% SDS-page gel and transferred to a PVDF membrane. The membrane was incubated in PERK, eIF2 and ATF4 antibodies overnight, washed three times with TBST the next day, and then added with secondary antibodies for 90 minutes. Color was developed in a chemiluminometer. It was found that the endoplasmic reticulum stress-related signal signals increased significantly after the use of isocladium lactone, indicating that isocladium lactone can promote the endoplasmic reticulum stress level ( Figure 7 E).
[0069] VII. Isophylline can inhibit the progression of pancreatic cancer in animal models
[0070] Animal experiments found that isocarpin inhibits pancreatic cancer in vivo
[0071] Four-week-old nude mice were purchased from Shanghai SLAC Laboratory Animal Company. All nude mice had free access to food and were maintained in an SPF environment. This experimental protocol complied with the ethical standards of the Animal Care and Use Committee of Zhejiang Chinese Medical University and complied with the Regulations on the Administration of Laboratory Animal Affairs (approved by the State Council of China, No. SYXK (Zhejiang) 2018-0012).
[0072] 1.5×10 6 CFPAC-1 cells were subcutaneously injected into the right side of the mice. Two weeks later, mice with the same tumor size were randomly divided into three groups (control group, low-dose group, high-dose group). The mice received an injection of the compound (DMSO, 5 mg / kg, 10 mg / kg) every three days ( Figure 8 A), and the weight of the mice and the length and width of the tumor were measured. After 21 days, the mice were humanely sacrificed, the tumors were removed, and the tumor volume (volume = 0.5 × length × width2) and weight were measured. The results showed that isocarpin can inhibit the proliferation of pancreatic cancer in vivo ( Figure 8 BE), the body weight of mice treated with isocladium lactone did not decrease significantly compared with the control group ( Figure 8 F).
[0073] The above description is only a preferred embodiment of the present invention, which is only illustrative and not restrictive of the present invention. Those skilled in the art understand that many changes, modifications, and even equivalences may be made to the present invention within the spirit and scope defined by the claims of the present invention, but all of them will fall within the scope of protection of the present invention.
Claims
1. A use of isocarpin as an endoplasmic reticulum stress agent in the preparation of a pancreatic cancer inhibitor, characterized in that: The structure of the iso-lindera lactone is as follows:
2. The use of isolindrospermum officinale as claimed in claim 1 as an endoplasmic reticulum stress agent in the preparation of a pancreatic cancer inhibitor, characterized in that: The pancreatic cancer cells are four pancreatic cancer cell lines, namely, ASPC-1, BXPC-3, CFPAC-1 and SW 1990.
3. The use of isolindrospermum officinale as claimed in claim 1 as an endoplasmic reticulum stress agent in the preparation of a pancreatic cancer inhibitor, characterized in that: The effective concentration of the isocarpin is 5 mg / kg to 10 mg / kg.
4. The use of isolindrospermum officinale as an endoplasmic reticulum stress agent in the preparation of a pancreatic cancer inhibitor as claimed in claim 1, characterized in that: In the in vitro test, the effective concentration of the isocarpin was ≥20 μM.
5. A use of isocladium lactone in the preparation of CFPAC-1 and SW 1990 cell invasion and migration inhibitors, characterized in that: In the in vitro test, the action concentration of the isocarpin was 20 μM to 40 μM, and the action time was 24 hours.
6. A use of iso-lindera lactone in the preparation of CFPAC-1 and SW 1990 cell cycle arrest and apoptosis promoter, characterized in that: In the in vitro test, the action concentration of the isocarpin was 20 μM to 40 μM, and the action time was 24 hours.
7. A use of iso-lindera lactone in the preparation of a p38 MAPK signaling pathway promoter in CFPAC-1 and SW 1990 cells, characterized in that: In the in vitro test, the action time of the isocarpin was 24 hours.
8. Use of isothiocyanate lactone in the preparation of endoplasmic reticulum stress promoter in CFPAC-1 and SW 1990 cells.
9. Use of isothiocyanate in the preparation of a promoter for the high expression of DDIT3 in CFPAC-1 and SW 1990 cells.
